Drugs Home > What Is Ibritumomab Used For?
Ibritumomab is prescribed for the treatment of a slow-growing form of non-Hodgkin's lymphoma in adults. It works by binding to the cancer cells, marking them for destruction by the immune system. Ibritumomab is also linked to an element that emits radiation to destroy surrounding cancer cells. There are no off-label, or unapproved, uses for ibritumomab at this time.
An Overview of Uses for IbritumomabIbritumomab (Zevalin®) is a prescription medication approved for the treatment of certain types of non-Hodgkin's lymphoma. It is given as an injection into a vein.
Non-Hodgkin's lymphoma is a type of cancer of the white blood cells (lymphocytes). It is often characterized by swollen lymph nodes, fever, and weight loss.
(Click Symptoms of Non-Hodgkin's Lymphoma for information on other possible signs of this type of cancer.)
There are several different types of non-Hodgkin's lymphoma. The types can be divided into cancers that are indolent (slow-growing or low-grade) or aggressive (fast-growing or high-grade), and further divided into cancers that form into B-lymphocytes (B-cells) or T-lymphocytes (T-cells). Follicular lymphoma is a common form of slow-growing, B-cell non-Hodgkin's lymphoma.
Ibritumomab is approved to treat low-grade, or follicular B-cell, non-Hodgkin's lymphoma that has not responded to previous treatment, or that has come back after being previously treated. It is also approved to treat people who are previously untreated for follicular non-Hodgkin's lymphoma, but only if they have a partial or complete response to a first-line treatment.